Soluble type III TGFβ receptor in diagnosis and follow-up of patients with breast cancer

被引：12

作者：

Jurisic, Darko ^{[1
]}

Erjavec, Igor ^{[2
]}

Trkulja, Vladimir ^{[3
]}

Dumic-Cule, Ivo ^{[2
]}

Hadzibegovic, Irzal ^{[4
]}

Kovacevic, Lucija ^{[2
]}

Svagusa, Tomo ^{[2
]}

Stanec, Zdenko ^{[5
]}

Vukicevic, Slobodan ^{[2
]}

Grgurevic, Lovorka ^{[2
]}

机构：

[1] Gen Hosp, Dept Surg, Slavonski Brod, Croatia

[2] Univ Zagreb, Sch Med, Ctr Translat & Clin Res, Lab Mineralized Tissues, Salata 11, HR-10000 Zagreb, Croatia

[3] Univ Zagreb, Sch Med, Dept Pharmacol, HR-10000 Zagreb, Croatia

[4] Gen Hosp, Dept Cardiol, Slavonski Brod, Croatia

[5] Univ Hosp Dubrava, Dept Plast Reconstruct & Aesthet Surg, Zagreb, Croatia

来源：

GROWTH FACTORS | 2015年 / 33卷 / 03期

关键词：

TGF; TGFrIII; betaglycan; breast cancer; biomarker; GROWTH-FACTOR-BETA; SUPPRESSES TUMORIGENICITY; MEMBRANE PROTEOGLYCAN; BETAGLYCAN; EXPRESSION; BONE; METASTASIS; INHIBITION; PATHWAY; POTENT;

D O I：

10.3109/08977194.2015.1055740

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Type III transforming growth factor (TGF) receptor (TGFrIII) modulates TGF superfamily signaling. Its tumor tissue expression is downregulated in human breast cancer. We determined (indirect ELISA) plasma levels of the soluble receptor (sTGFrIII) in 47 women with breast cancer (AJCC stages 0-IIB) (cases) pre-surgery and over two months after the surgery, and in 36 healthy women (controls). Plasma sTBFrIII was lower in cases than in the controls (age-adjusted difference -29.7ng/mL, p<0.001), and discriminated between disease and health (sensitivity and specificity 100% at 16.6ng/mL). With adjustment for age, AJCC stage, lymph node involvement, HER2 and hormone receptor status, higher pre-surgery sTBFrIII was associated with better progression-free survival (HR=0.68, 95%CI 0.49-0.89, p=0.004). An increasing trend in plasma sTBFrIII was observed over 2 months after the surgery (0.6% increase/day, p<0.001), consistently across the patient subsets. Data suggest a high potential of plasma sTBFrIII as a novel diagnostic and prognostic biomarker in breast cancer.

引用

页码：200 / 209

页数：10

共 50 条

[1] Diagnosis, staging and follow-up in breast cancer patients
Stickeler, Elmar
BREAST CARE, 2007, 2 (03) : 158 - 162
[2] Benefit of scintimammography in diagnosis and follow-up of patients with breast cancer
Malesevic, M
Mihailovic, J
Golubovic, A
Stoiljkovic, B
Beric, O
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S344 - S345
[3] Follow-Up after Breast Cancer Diagnosis
Thomssen, Christoph
Diel, Ingo
Gnant, Michael
Goldmann-Posch, Ursula
Goeschke, Christiane
Haidinger, Renate
Janni, Wolfgang
Lin, Nancy U.
BREAST CARE, 2013, 8 (06) : 457 - 460
[4] VALUE OF LABORATORY DIAGNOSIS IN FOLLOW-UP OF BREAST-CANCER PATIENTS
SCHMIDTRHODE, P
FRIEBE, M
ZWIOREK, L
SCHULZ, KD
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 814 - 816
[5] The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer
Woeckel, Achim
Albert, Ute-Susann
Janni, Wolfgang
Scharl, Anton
Kreienberg, Rolf
Stueber, Tanja
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (18): : 316 - +
[6] The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer
Bussmann, Peter
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2019, 116 (1-2): : 9 - 9
[7] FOLLOW-UP IN BREAST-CANCER - PATIENTS PREFER SPECIALIST FOLLOW-UP
MAHER, J
BRADBURN, J
ADEWUYIDALTON, R
BRITISH MEDICAL JOURNAL, 1995, 311 (6996): : 54 - 54
[8] FOLLOW-UP OF PATIENTS WITH BREAST-CANCER
PACE, BW
TINKER, MA
CLINICAL OBSTETRICS AND GYNECOLOGY, 1994, 37 (04): : 998 - 1002
[9] Radiodiagnostics in the follow-up of breast cancer patients
Dieterich, Max
Gerber, Bernd
BREAST CARE, 2007, 2 (06) : 365 - 370
[10] Follow-up of patients with early breast cancer
Butsch, W. Scott
Munoz, Andres J.
Heimburger, Douglas C.
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (10): : 1053 - 1053

← 1 2 3 4 5 →